Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.2.1.31 (beta-glucuronidase)
 7,680 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The turnover properties of murine beta-glucuronidase in several tissues and at two subcellular sites have been determined by monitoring the radioactivity present in immunoprecipitated enzyme at a number of time points following the in vivo administration of a single radiolabeled protein precursor (either L-[3,4(-3H)]leucine or or NaH14CO3). In all experiments a considerable period of time was required for the attainment of maximum specific radioactivity in glucuronidase. Similar labeling kinetics was found when [3H]leucine incorporation was monitored in immunoprecipitated murine liver delta-aminolevulinate dehydratase. Half-life estimates of 2 to 3 days were obtained for glucuronidases of liver, kidney, and spleen. In most strains of inbred mice, it is known that approximately 60% of total liver glucuronidase activity resides in lysosomes, while 40% is within the membranes of the endoplasmic reticulum (Ganschow, R. E. and Paigen, K. (1968) Genetics 59, 335-349). These two subcellular forms of glucuronidase turn over at similar rates. Furthermore, the bulk of glucuronidase in the endoplasmic reticulum does not serve as precursor to lysosomal glucuronidase.
 ...
PMID:Turnover of murine beta-glucuronidase. Comparison among liver, kidney, and spleen and between lysosomes and microsomes. 67 Feb 6

The combined therapeutic potentials of lipoic acid and dimercaptosuccinic acid were compared against their sole administrations in restoring the altered lead sensitive indices in urine and isolated renal brush-border preparations. Toxicity was induced in male albino rats (Wistar strain) by administering lead acetate (0.2%) in drinking water for 5 weeks, followed by therapy comprising lipoic acid (25 mg/kg body weight) and dimercaptosuccinic acid (20 mg/kg body weight) solely as well as combined during the 6th week. Changes in kidney weights encountered upon lead administration improved after therapy with lipoic acid and dimercaptosuccinic acid. Renal integrity was assessed by measuring the activities of alkaline phosphatase, acid phosphatase, lactate dehydrogenase, leucine aminopeptidase, N-acetyl-beta-D-glucosaminidase, gamma-glutamyl transferase and beta-glucuronidase in urine along with some urinary constituents (urea, uric acid, creatinine, protein and phosphorous). The effects of lead were also studied on isolated brush-border enzymes (alkaline phosphatase, acid phosphatase, gamma-glutamyl transferase and beta-glucuronidase) that showed a decline upon its administration. Increased activities of urinary enzymes were accompanied by increase in the urinary constituents. Increase in renal lead content was paralleled by a drastic fall in the renal delta-aminolevulinic acid dehydratase and a rise in urinary lead levels. Relative to the administration of lead, the combined therapy showed betterment on the renal integrity with respect to the functional parameters assessed, thereby indicating its efficacy over the monotherapies.
 ...
PMID:Therapeutic efficacy of lipoic acid in combination with dimercaptosuccinic acid against lead-induced renal tubular defects and on isolated brush-border enzyme activities. 1513 82